

Tessa L Holyoake

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2686052/tessa-l-holyoake-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

208 papers	12,468 citations	51 h-index	110 g-index
216 ext. papers	13,698 ext. citations	6 avg, IF	5.82 L-index

#	Paper	IF	Citations
208	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012 , 8, 445-544.	14.2	2783
207	Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. <i>Blood</i> , 2002 , 99, 319-25	2.2	969
206	Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. <i>Blood</i> , 2006 , 107, 4532-9	2.2	542
205	Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. <i>Journal of Clinical Investigation</i> , 2009 , 119, 1109-23	15.9	439
204	Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia. <i>Blood</i> , 1999 , 94, 2056-2064	2.2	424
203	Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. <i>Cancer Cell</i> , 2012 , 21, 266-81	24.3	323
202	Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. <i>Blood</i> , 2012 , 119, 1501-10	2.2	301
201	Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. <i>Blood</i> , 2007 , 109, 4016-9	2.2	266
200	Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. <i>Cancer Cell</i> , 2012 , 21, 577-92	24.3	257
199	Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells. <i>Nature Medicine</i> , 2017 , 23, 1234-1240	50.5	247
198	Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. <i>Cancer Cell</i> , 2010 , 17, 427-42	24.3	219
197	Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- β -catenin signaling. <i>Blood</i> , 2013 , 121, 1824-38	2.2	192
196	The chronic myeloid leukemia stem cell: stemming the tide of persistence. <i>Blood</i> , 2017 , 129, 1595-1606	2.2	171
195	PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4144-57	15.9	170
194	Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. <i>Blood</i> , 2000 , 95, 1883-1890	2.2	155
193	Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. <i>Nature</i> , 2016 , 534, 341-6	50.4	141
192	Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. <i>Blood</i> , 2014 , 123, 3951-62	2.2	140

191	Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. <i>Blood</i> , 2006 , 108, 1370-3	2.2	140
190	Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. <i>Blood</i> , 2001 , 97, 720-8	2.2	139
189	Punish the parent not the progeny. <i>Blood</i> , 2005 , 105, 1862-6	2.2	131
188	Loss or inhibition of stromal-derived PLGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. <i>Cancer Cell</i> , 2011 , 19, 740-53	24.3	115
187	Rac2-MRC-cll-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. <i>Blood</i> , 2012 , 119, 4253-63	2.2	110
186	BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. <i>Blood</i> , 2008 , 111, 2843-53	2.2	108
185	Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. <i>Clinical Cancer Research</i> , 2007 , 13, 5048-55	12.9	103
184	JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. <i>Blood</i> , 2014 , 124, 1492-501	2.2	101
183	Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. <i>Blood</i> , 2011 , 118, 2035-43	2.2	93
182	Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2010 , 95, 224-31	6.6	93
181	Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. <i>Blood</i> , 2008 , 111, 2329-38	2.2	91
180	Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. <i>Blood</i> , 2013 , 121, 4175-83	2.2	84
179	Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. <i>Blood</i> , 2007 , 109, 1701-11	2.2	84
178	Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition. <i>Cancer Discovery</i> , 2016 , 6, 1248-1257	24.4	82
177	A consensus on fungal polymerase chain reaction diagnosis?: a United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 376-84	5.1	82
176	Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. <i>Clinical Cancer Research</i> , 2006 , 12, 626-33	12.9	81
175	Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. <i>Cancer Research</i> , 2008 , 68, 9624-33	10.1	77
174	BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. <i>Blood</i> , 2010 , 115, 3185-95	2.2	75

173	Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. <i>Blood</i> , 2002 , 99, 713-5	2.2	72
172	The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. <i>Stem Cells</i> , 2014 , 32, 2324-37	5.8	71
171	Megakaryocytes assemble podosomes that degrade matrix and protrude through basement membrane. <i>Blood</i> , 2013 , 121, 2542-52	2.2	70
170	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. <i>Nature Medicine</i> , 2018 , 24, 450-462	50.5	69
169	Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources. <i>Stem Cells</i> , 2007 , 25, 3111-20	5.8	69
168	Autocrine TNF- α production supports CML stem and progenitor cell survival and enhances their proliferation. <i>Blood</i> , 2013 , 122, 3335-9	2.2	67
167	Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. <i>Blood</i> , 2016 , 128, 2671-2682	2.2	67
166	ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells. <i>Autophagy</i> , 2016 , 12, 936-48	10.2	65
165	Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 405-23	9.7	63
164	Targeting quiescent leukemic stem cells using second generation autophagy inhibitors. <i>Leukemia</i> , 2019 , 33, 981-994	10.7	63
163	Telomere length dynamics in normal individuals and in patients with hematopoietic stem cell-associated disorders. <i>Annals of the New York Academy of Sciences</i> , 2001 , 938, 293-303; discussion 303-4	6.5	61
162	Hif-2 β is not essential for cell-autonomous hematopoietic stem cell maintenance. <i>Blood</i> , 2013 , 122, 1741-52	5.2	60
161	Targeting survival pathways in chronic myeloid leukaemia stem cells. <i>British Journal of Pharmacology</i> , 2013 , 169, 1693-707	8.6	56
160	The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. <i>Blood</i> , 2013 , 121, 628-37	2.2	56
159	Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia. <i>Scientific Reports</i> , 2016 , 6, 25476	4.9	54
158	Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 467-478	9.7	51
157	Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny. <i>PLoS ONE</i> , 2012 , 7, e51363	3.7	50
156	Adult hematopoietic stem cells lacking Hif-1 β self-renew normally. <i>Blood</i> , 2016 , 127, 2841-6	2.2	48

155	Hif-1 α and Hif-2 α synergize to suppress AML development but are dispensable for disease maintenance. <i>Journal of Experimental Medicine</i> , 2015 , 212, 2223-34	16.6	47
154	Concise review: Telomere biology in normal and leukemic hematopoietic stem cells. <i>Stem Cells</i> , 2007 , 25, 1853-61	5.8	47
153	Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. <i>PLoS Computational Biology</i> , 2009 , 5, e1000503	5	45
152	Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. <i>Blood</i> , 2010 , 115, 2241-50	2.2	44
151	Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. <i>Blood</i> , 2010 , 116, 2112-21	2.2	44
150	Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3847-62	15.9	44
149	CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression. <i>Blood</i> , 2017 , 129, 199-208	2.2	42
148	Autophagy in blood cancers: biological role and therapeutic implications. <i>Haematologica</i> , 2013 , 98, 1335-48	4.8	42
147	BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase C β . <i>Blood</i> , 2009 , 114, 4186-96	2.2	42
146	DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia. <i>European Journal of Clinical Investigation</i> , 2014 , 44, 1239-45	4.6	39
145	Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML. <i>Clinical Cancer Research</i> , 2016 , 22, 2051-61	12.9	38
144	Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1775-81	1.9	38
143	HOXA5 is targeted by cell-type-specific CpG island methylation in normal cells and during the development of acute myeloid leukaemia. <i>Carcinogenesis</i> , 2007 , 28, 299-309	4.6	36
142	Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro. <i>PLoS ONE</i> , 2011 , 6, e19164	3.7	35
141	Do we need more drugs for chronic myeloid leukemia?. <i>Immunological Reviews</i> , 2015 , 263, 106-23	11.3	34
140	Evolving molecular therapy for chronic myeloid leukaemia--are we on target?. <i>Hematology</i> , 2005 , 10, 349-59	2.2	34
139	The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. <i>Molecular Biotechnology</i> , 2007 , 36, 81-9	3	31
138	Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 2289-2300	12.9	30

137	Role of autophagy in cancer prevention, development and therapy. <i>Essays in Biochemistry</i> , 2013 , 55, 133-56	3.6	30
136	Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. <i>Experimental Hematology</i> , 2009 , 37, 692-700	3.1	29
135	Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. <i>Leukemia</i> , 2012 , 26, 1555-63	10.7	29
134	-mediated regulation of E2F1 is required for CML stem/progenitor cell survival. <i>Blood</i> , 2018 , 131, 1532-1544	5.4	28
133	CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. <i>Blood</i> , 2016 , 128, 371-83	2.2	28
132	A multinational study of health state preference values associated with chronic myelogenous leukemia. <i>Value in Health</i> , 2010 , 13, 103-11	3.3	28
131	Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy. <i>Current Cancer Drug Targets</i> , 2013 , 13, 724-34	2.8	26
130	Targeting chronic myeloid leukemia stem cells. <i>Current Hematologic Malignancy Reports</i> , 2010 , 5, 81-7	4.4	26
129	Targeted therapy in haematological malignancies. <i>Journal of Pathology</i> , 2010 , 220, 404-18	9.4	26
128	Therapeutic targets in chronic myeloid leukaemia. <i>Hematological Oncology</i> , 2007 , 25, 66-75	1.3	26
127	Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells. <i>Cancer Research</i> , 2010 , 70, 7949-59	10.1	25
126	Uptake of synthetic Low Density Lipoprotein by leukemic stem cells--a potential stem cell targeted drug delivery strategy. <i>Journal of Controlled Release</i> , 2010 , 148, 380-7	11.7	25
125	Mtss1 is a critical epigenetically regulated tumor suppressor in CML. <i>Leukemia</i> , 2016 , 30, 823-32	10.7	24
124	Can we afford to let sleeping dogs lie?. <i>Blood</i> , 2005 , 105, 1840-1	2.2	24
123	Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). <i>British Journal of Haematology</i> , 2010 , 149, 65-9	4.5	23
122	Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting. <i>Stem Cells</i> , 2014 , 32, 1373-9	5.8	22
121	Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks. <i>Journal of Experimental Medicine</i> , 2011 , 208, 2155-8	16.6	22
120	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2020 , 34, 1613-1625	10.7	22

119	Preclinical approaches in chronic myeloid leukemia: from cells to systems. <i>Experimental Hematology</i> , 2017 , 47, 13-23	3.1	21
118	A pathway from leukemogenic oncogenes and stem cell chemokines to RNA processing via THOC5. <i>Leukemia</i> , 2013 , 27, 932-40	10.7	20
117	In search of CML stem cells' deadly weakness. <i>Current Hematologic Malignancy Reports</i> , 2011 , 6, 82-7	4.4	19
116	The chronic myeloid leukemia stem cell. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9 Suppl 4, S376-81		19
115	Prevalence and haemopoietic effects of low serum vitamin B12 levels in geriatric medical patients. <i>British Journal of Nutrition</i> , 1997 , 78, 57-63	3.6	19
114	Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. <i>British Journal of Haematology</i> , 2003 , 123, 479-83	4.5	19
113	Evolution of bone marrow transplantation--the original immunotherapy. <i>Trends in Immunology</i> , 2001 , 22, 88-92	14.4	18
112	Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines. <i>Nature Protocols</i> , 2015 , 10, 149-68	18.8	17
111	Hurdles toward a cure for CML: the CML stem cell. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 951-66, v	3.1	17
110	The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues. <i>Haematologica</i> , 2011 , 96, 590-601	6.6	17
109	Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. <i>Haematologica</i> , 2011 , 96, 1779-82	6.6	17
108	Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 120, 4441-3	2.2	16
107	Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. <i>Experimental Hematology</i> , 2005 , 33, 1140-6	3.1	16
106	A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type β in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 129	22.4	15
105	Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 381-92	3.5	15
104	Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia. <i>Blood</i> , 2008 , 111, 5252-5	2.2	15
103	Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models. <i>Oncogenesis</i> , 2014 , 3, e90	6.6	14
102	A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia. <i>Hematological Oncology</i> , 2001 , 19, 89-106	1.3	14

101	Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. <i>Blood</i> , 2014 , 124, 517-517	2.2	14
100	Dual glutathione-S-transferase- α and - β gene deletions determine imatinib failure in chronic myeloid leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 694-703	6.1	13
99	Poor performance of galactomannan and mannan sandwich enzyme-linked immunosorbent assays in the diagnosis of invasive fungal infection. <i>British Journal of Haematology</i> , 2005 , 128, 578-9	4.5	13
98	Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. <i>Cancer</i> , 2005 , 103, 210-11	6.4	13
97	Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia. <i>Blood</i> , 1999 , 94, 2056-2064	2.2	13
96	A specific PTPRC/CD45 phosphorylation event governed by stem cell chemokine CXCL12 regulates primitive hematopoietic cell motility. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 3319-29	7.6	12
95	Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data. <i>Blood Reviews</i> , 2010 , 24, 1-9	11.1	12
94	Redirecting traffic using the XPO1 police. <i>Blood</i> , 2013 , 122, 2926-8	2.2	11
93	Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells. <i>Blood Cancer Journal</i> , 2012 , 2, e71	7	11
92	Response: Conventional Western blotting techniques will not reliably quantify p210 BCR-ABL. <i>Blood</i> , 2007 , 109, 1336-1336	2.2	11
91	Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia. <i>Oncotarget</i> , 2016 , 7, 51651-51664	3.3	11
90	BRD4-mediated repression of p53 is a target for combination therapy in AML. <i>Nature Communications</i> , 2021 , 12, 241	17.4	11
89	Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells. <i>Experimental Hematology</i> , 2009 , 37, 395-401	3.1	9
88	In vivo expansion of the endogenous B-cell compartment stimulated by radiation and serial bone marrow transplantation induces B-cell leukaemia in mice. <i>British Journal of Haematology</i> , 2001 , 114, 49-56	4.5	9
87	Combination of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib Eliminates Chronic Myeloid Leukemia Stem and Progenitor Cells.. <i>Blood</i> , 2009 , 114, 1428-1428	2.2	9
86	CD34+ cells can be selected efficiently from cryopreserved peripheral blood progenitor cells and can retain their proliferative potential. <i>Stem Cells and Development</i> , 1997 , 6, 501-10		8
85	Effective Induction of Apoptosis in Chronic Myeloid Leukemia CD34+ Cells by the Histone Deacetylase Inhibitor LAQ824 in Combination with Imatinib.. <i>Blood</i> , 2007 , 110, 1031-1031	2.2	8
84	BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2012 , 157, 446-56	4.5	7

83	Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study. <i>British Journal of Haematology</i> , 2011 , 155, 128-30	4.5	7
82	Predictive response-relevant clustering of expression data provides insights into disease processes. <i>Nucleic Acids Research</i> , 2010 , 38, 6831-40	20.1	7
81	Isolation and therapeutic potential of human haemopoietic stem cells. <i>Cytotechnology</i> , 2003 , 41, 111-31	2.2	7
80	The number of CD34+ cells mobilized into the peripheral blood can predict the quality of subsequent collections. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000 , 9, 89-93		7
79	Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. <i>Blood</i> , 2015 , 126, 4024-4024	2.2	7
78	Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. <i>British Journal of Haematology</i> , 2013 , 163, 674-6	4.5	6
77	BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.. <i>Blood</i> , 2006 , 108, 739-739	2.2	6
76	Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib. <i>Blood</i> , 2010 , 116, 514-514	2.2	6
75	Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients. <i>Proteomics</i> , 2013 , 13, 153-68	4.8	5
74	Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. <i>Blood Cells, Molecules, and Diseases</i> , 2012 , 48, 199-201	2.1	5
73	FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. <i>Blood</i> , 2009 ,	2.2	5
72	BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment. <i>Blood</i> , 2010 , 116, 515-515	2.2	5
71	Investigation of a minor groove-binding polyamide targeted to E2F1 transcription factor in chronic myeloid leukaemia (CML) cells. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 69, 119-122	2.1	5
70	Cancer: Repositioned to kill stem cells. <i>Nature</i> , 2015 , 525, 328-9	50.4	4
69	Lifting the Differentiation Embargo. <i>Cell</i> , 2016 , 167, 45-46	56.2	4
68	Published rather than proposed definitions for invasive fungal infection must be applied to allow standardization in clinical trials. <i>Clinical Infectious Diseases</i> , 2004 , 38, 1648-9	11.6	4
67	Stem cells in chronic myeloid leukaemia. <i>Cancer Biomarkers</i> , 2007 , 3, 183-91	3.8	3
66	Imatinib Mesylate Does Not Inhibit BCR-ABL Kinase Activity in CML Stem Cells In Vitro.. <i>Blood</i> , 2004 , 104, 1979-1979	2.2	3

65	BMS-214662 Targets Quiescent Chronic Myeloid Leukaemia Stem Cells and Enhances the Activity of Both Imatinib and Dasatinib (BMS-354825).. <i>Blood</i> , 2005 , 106, 693-693	2.2	3
64	Nilotinib concentration in Cell Lines and CML CD34+ Cells Is Not Mediated by Active Uptake or Efflux by Major Drug Transporters. <i>Blood</i> , 2008 , 112, 3205-3205	2.2	3
63	Investigation into omacetaxine solution stability for in vitro study. <i>Biomedical Chromatography</i> , 2012 , 26, 545-7	1.7	2
62	Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells. <i>Experimental Hematology</i> , 2009 , 37, 206-14	3.1	2
61	High loading dose AmBisome is efficacious and well tolerated in the management of invasive fungal infection in hematology patients. <i>Haematologica</i> , 2007 , 92, 572-3	6.6	2
60	Enhanced Primary CML Stem Cell Elimination by Bryostatin Priming with Imatinib Mesylate In Vitro.. <i>Blood</i> , 2004 , 104, 1997-1997	2.2	2
59	Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.. <i>Blood</i> , 2005 , 106, 1997-1997	2.2	2
58	Dasatinib (BMS-354825) Has Increased Activity Against Bcr-Abl Compared to Imatinib in Primary CML Cells In Vitro, but Does Not Eradicate Quiescent CML Stem Cells.. <i>Blood</i> , 2005 , 106, 695-695	2.2	2
57	A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib.. <i>Blood</i> , 2007 , 110, 1033-1033	2.2	2
56	Bortezomib Has Anti-Proliferative and Apoptotic Effects Against CML Stem Cells, Including the Quiescent Population.. <i>Blood</i> , 2007 , 110, 2943-2943	2.2	2
55	Foxo Transcription Factor Activity Is Retained in Quiescent Chronic Myeloid Leukaemia Stem Cells and Activated by Tyrosine Kinase Inhibitors to Mediate Induced-quiescence In More Mature progenitors.. <i>Blood</i> , 2009 , 114, 187-187	2.2	2
54	Therapy Resistant CML Stem Cells Are Dependent on Mitochondrial Oxidative Metabolism for Their Survival. <i>Blood</i> , 2016 , 128, 932-932	2.2	2
53	Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS. <i>Pakistan Journal of Pharmaceutical Sciences</i> , 2011 , 24, 285-91	0.4	2
52	Models to Study Chronic Myeloid Leukemia Cancer Stem Cells 2014 , 119-131		1
51	Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. <i>Cancer</i> , 2003 , 98, 1776-7; author reply 1777-8	6.4	1
50	Acute Cardiotoxicity After Daunorubicin in Acute Myeloid Leukaemia. <i>Leukemia and Lymphoma</i> , 1991 , 3, 305-7	1.9	1
49	Nilotinib Inhibits Bcr-Abl Kinase Activity in CML Progenitor Cells More Effectively Than Imatinib but Is Equipotent in Inducing Growth Inhibition.. <i>Blood</i> , 2006 , 108, 744-744	2.2	1
48	Normal Short-Term but Reduced Long-Term Engraftment Capacity of CML Hematopoietic Cells with Skewed Myeloid Lineage Differentiation Is Seen in an Improved Mouse Model of Human Hematopoiesis.. <i>Blood</i> , 2007 , 110, 3383-3383	2.2	1

47	Targeting Autophagy Potentiates Imatinib-Induced Cell Death in Philadelphia Positive Cells Including Primary CML Stem Cells.. <i>Blood</i> , 2008 , 112, 1070-1070	2.2	1
46	Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with Imatinib.. <i>Blood</i> , 2009 , 114, 1724-1724	2.2	1
45	Inhibition Of Microenvironmental Interleukin-1 Signaling Enhances TKI-Mediated Targeting Of Chronic Myelogenous Leukemia Stem Cells. <i>Blood</i> , 2013 , 122, 512-512	2.2	1
44	Cytomegalovirus Infection Is Associated with Expansions of CD8 T Cells and Highly Oligoclonal Vdelta1 Gamma/Delta T Cells in Patients Treated with Dasatinib for Chronic Myelogenous Leukaemia. <i>Blood</i> , 2014 , 124, 1814-1814	2.2	1
43	Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2016 , 128, 3057-3057	2.2	1
42	G-CSF as a Potent Mitogen Augments the Elimination of CML Stem Cells by Imatinib Mesylate In Vitro.. <i>Blood</i> , 2004 , 104, 2941-2941	2.2	1
41	Reversible Transplantable Chronic Phase CML-Like Disease in SCLtTA/BCR-ABL Transgenic Mice.. <i>Blood</i> , 2007 , 110, 1002-1002	2.2	1
40	BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. <i>Blood</i> , 2014 , 124, 4512-4512	2.2	1
39	Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.. <i>Blood</i> , 2010 , 116, 3404-3404	2.2	1
38	Inhibition of Autophagy in Combination with Ponatinib or Dual PI3K/mTOR Inhibition to Improve Treatment Response for Both Bcr-Abl Dependent and Independent Mechanisms of TKI-Resistance in CML. <i>Blood</i> , 2012 , 120, 1664-1664	2.2	1
37	Microenvironmental Protection of CML Stem and Progenitor Cells From Tyrosine Kinase Inhibitors Through N-Cadherin and Wnt Signaling. <i>Blood</i> , 2012 , 120, 912-912	2.2	1
36	Oncogene Addiction in Chronic Myeloid Leukaemia1-9		0
35	Bayesian inference for model selection: an application to aberrant signalling pathways in chronic myeloid leukaemia161-190		
34	GATA1 mutational analysis in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2007 , 137, 375-385	4.5	
33	BCR-ABL FISH monitoring of CML: a survey of current UK practice. <i>British Journal of Haematology</i> , 2002 , 119, 272-3	4.5	
32	Functional ABCG2 Is Expressed on CML Stem Cells and Its Inhibition Selectively Depletes CML CD34+ Cells.. <i>Blood</i> , 2004 , 104, 716-716	2.2	
31	Gene Expression Profiling in Quiescent Stem Cells from Normal and Chronic Myeloid Leukaemia Patients.. <i>Blood</i> , 2004 , 104, 2962-2962	2.2	
30	The Role of DNA Methylation of HoxA5, a Regulator of Haematopoiesis, in Progression to Myeloid Blast Crisis in CML.. <i>Blood</i> , 2004 , 104, 2053-2053	2.2	

- 29 Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.. *Blood*, **2005**, 106, 1125-1125 2.2
- 28 Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.. *Blood*, **2006**, 108, 1379-1379 2.2
- 27 The Dual Src/Abl Kinase Inhibitor SKI-606 Effectively Inhibits Bcr-Abl Kinase Activity and Reduces Proliferation of CML Primitive Progenitor Cells.. *Blood*, **2006**, 108, 1370-1370 2.2
- 26 Protection of CML Progenitors from Bcr-Abl Tyrosine Kinase Inhibitor Mediated Apoptosis by the Bone Marrow Stromal Microenvironment.. *Blood*, **2007**, 110, 3378-3378 2.2
- 25 Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusion after Imatinib Induction To Eradicate Residual Disease in Chronic Myeloid Leukaemia.. *Blood*, **2007**, 110, 1097-1097 2.2
- 24 Effect of Dasatinib on BCR-ABL and Src Mediated Growth Signaling in Primary CML Hematopoietic Progenitors.. *Blood*, **2007**, 110, 2944-2944 2.2
- 23 HOX Genes - Candidate Tumor Suppressor Genes in Adult and Childhood Leukemia.. *Blood*, **2007**, 110, 2641-2641 2.2
- 22 Role of Enhanced Microenvironmental Interleukin-1 (IL-1) Expression and Increased IL-1 Responsiveness in Persistence of Leukemia Stem Cells in TKI Treated CML Patients. *Blood*, **2014**, 124, 4357-4357 2.2
- 21 Effective and Selective Elimination of CML Stem Cells Using Novel Ethacrynic Acid Derivatives. *Blood*, **2014**, 124, 4508-4508 2.2
- 20 Reliable Detection of Abl Tyrosine Kinase Domain Mutations to . *Blood*, **2015**, 126, 4021-4021 2.2
- 19 BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. *Blood*, **2015**, 126, 1569-1569 2.2
- 18 Growth Factor Deprivation Combined with Prolonged Inhibition of BCR-ABL Does Not Eradicate Functional CML Stem Cells. *Blood*, **2008**, 112, 4222-4222 2.2
- 17 Mtss1 Suppresses BCR-ABL Induced Cell Migration and Is Downregulated in CML Stem Cells.. *Blood*, **2008**, 112, 1077-1077 2.2
- 16 Combination Therapy of Small Molecule Inhibitor PHA-739358 and Tyrosine Kinase Inhibitor Imatinib Yields Synergistic Antiproliferative Effects and Suppresses Emergence of Resistance of Chronic Myeloid Leukemia in Vitro. *Blood*, **2008**, 112, 3227-3227 2.2
- 15 N-Cadherin-Mediated Microenvironmental Interactions Protect CML Stem Cells from Imatinib Mediated Apoptosis.. *Blood*, **2008**, 112, 1073-1073 2.2
- 14 Stem Cells in Leukemia and Other Hematological Malignancies **2009**, 111-136
- 13 Effective Targeting of Quiescent CML Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate.. *Blood*, **2009**, 114, 190-190 2.2
- 12 Placental Growth Factor: a Novel, Stromal-Derived Target in Human CML.. *Blood*, **2009**, 114, 42-42 2.2

- 11 Alterations In Wnt Signalling In the Megakaryocytic Lineage Leads to Bone Marrow Failure and Myelofibrosis. *Blood*, **2010**, 116, 628-628 2.2
- 10 BMS-214662 Eliminates Quiescent and Proliferating Acute Myeloid Leukemia Cells through Activation of Protein Kinase C β and Enhances the Efficacy of Cytosine Arabinoside. *Blood*, **2010**, 116, 2167-2167 2.2
- 9 SIRT1 Inhibition Induces Apoptosis In Human CML Progenitors by Enhancing p53 Acetylation and Activation. *Blood*, **2010**, 116, 200-200 2.2
- 8 Leukemia-Induced Alterations in Bone Marrow Cytokine and Chemokine Levels Contribute to Altered Stem Cell Lodgment and Impairment of Normal Stem Cell Growth in CML. *Blood*, **2011**, 118, 962-962 2.2
- 7 Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells. *Blood*, **2011**, 118, 2736-2736 2.2
- 6 Pharmacological Inhibition of the Stress-Related Deacetylase SIRT1 Enhances Eradication of CML stem Cells. *Blood*, **2011**, 118, 448-448 2.2
- 5 Metastasis Suppressor 1 Is Downregulated in CML Stem Cells and Overexpression Impairs Early Leukemic Cell Propagation.. *Blood*, **2012**, 120, 2776-2776 2.2
- 4 p53 and c-Myc Are Critical Signaling Hubs That Maintain Chronic Myeloid Leukemia. *Blood*, **2013**, 122, 1465-1465 2.2
- 3 HIF-1 α Is Not Essential For The Establishment Of MLL-Leukaemic Stem Cells. *Blood*, **2013**, 122, 3767-3767 2.2
- 2 Axl Represents a Therapeutic Target In T315I-Mutated and WT Chronic Myeloid Leukemia. *Blood*, **2013**, 122, 1469-1469 2.2
- 1 Misregulation Of The PRC2 Complex In CML Stem Cells Confers Sensitivity To An EZH2 Inhibitor. *Blood*, **2013**, 122, 2710-2710 2.2